{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:38:00Z","timestamp":1788799080990,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jtcvsonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Thoracic and Cardiovascular Surgery"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.jtcvs.2020.02.131","type":"journal-article","created":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T23:42:29Z","timestamp":1584574949000},"page":"434-442.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":88,"title":["Gefitinib as neoadjuvant therapy for resectable stage II-IIIA non\u2013small cell lung cancer: A phase II study"],"prefix":"10.1016","volume":"161","author":[{"given":"Yang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangqiu","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haichuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiquan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtcvs.2020.02.131_bib1","first-page":"115","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jtcvs.2020.02.131_bib2","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/ijc.31937","article-title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods","volume":"144","author":"Ferlay","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jtcvs.2020.02.131_bib3","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jtcvs.2020.02.131_bib4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM Classification for Lung Cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtcvs.2020.02.131_bib5","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.athoracsur.2014.05.070","article-title":"Differences in patterns of recurrence in early-stage versus locally advanced non-small cell lung cancer","volume":"98","author":"Lou","year":"2014","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtcvs.2020.02.131_bib6","doi-asserted-by":"crossref","first-page":"iv1-iv21","DOI":"10.1093\/annonc\/mdx222","article-title":"Early and locally advanced non\u2013small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Postmus","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtcvs.2020.02.131_bib7","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/S0140-6736(13)62159-5","article-title":"Preoperative chemotherapy for non\u2013small-cell lung cancer: a systematic review and meta-analysis of individual participant data","volume":"383","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jtcvs.2020.02.131_bib8","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Shi","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtcvs.2020.02.131_bib9","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1470-2045(17)30729-5","article-title":"Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT\/CTONG1104): a randomised, open-label, phase 3 study","volume":"19","author":"Zhong","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtcvs.2020.02.131_bib10","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtcvs.2020.02.131_bib11","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/JTO.0b013e318247504a","article-title":"Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy","volume":"7","author":"Pataer","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtcvs.2020.02.131_bib12","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S1470-2045(13)70334-6","article-title":"Pathological response after neoadjuvant chemotherapy in resectable non\u2013small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint","volume":"15","author":"Hellmann","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtcvs.2020.02.131_bib13","doi-asserted-by":"crossref","first-page":"157.e64","DOI":"10.1634\/theoncologist.2018-0120","article-title":"Erlotinib as neoadjuvant therapy in stage IIIA (N2) EGFR mutation-positive non-small cell lung cancer: a prospective, single-arm, phase II study","volume":"24","author":"Xiong","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.jtcvs.2020.02.131_bib14","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1200\/JCO.19.00075","article-title":"Erlotinib versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): a randomized phase II study","volume":"37","author":"Zhong","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtcvs.2020.02.131_bib15","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1200\/JCO.2015.61.8918","article-title":"Adjuvant Erlotinib versus Placebo in Patients with Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): a randomized, double-blind, phase III trial","volume":"33","author":"Kelly","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtcvs.2020.02.131_bib16","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1200\/JCO.2013.51.1816","article-title":"Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study","volume":"31","author":"Goss","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtcvs.2020.02.131_bib17","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/JTO.0000000000000053","article-title":"Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non\u2013small-cell lung cancer treated with gefitinib or erlotinib","volume":"9","author":"Takeda","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtcvs.2020.02.131_bib18","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1200\/JCO.2013.52.3019","article-title":"Evaluation of alternate categorical tumor metrics and cut points for response categorization using the RECIST 1.1 data warehouse","volume":"32","author":"Mandrekar","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtcvs.2020.02.131_bib19","doi-asserted-by":"crossref","first-page":"e0194841","DOI":"10.1371\/journal.pone.0194841","article-title":"Pre-treatment tumour perfusion parameters and initial RECIST response do not predict long-term survival outcomes for patients with head and neck squamous cell carcinoma treated with induction chemotherapy","volume":"13","author":"Lowe","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jtcvs.2020.02.131_bib20","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/JTO.0b013e3182774108","article-title":"Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy","volume":"8","author":"William","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtcvs.2020.02.131_bib21","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1097\/JTO.0b013e31829923ec","article-title":"Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers","volume":"8","author":"Chaft","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtcvs.2020.02.131_bib22","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtcvs.2020.02.131_bib23","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1001\/jama.290.16.2149","article-title":"Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non\u2013small cell lung cancer: a randomized trial","volume":"290","author":"Kris","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jtcvs.2020.02.131_bib24","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1002\/cam4.1785","article-title":"Would 1.0 cm be a more suitable cutoff to subdivide pT1 tumors in hormone receptor-negative and HER2-positive breast cancer?","volume":"7","author":"Wang","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.jtcvs.2020.02.131_bib25","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.lungcan.2018.06.032","article-title":"Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC","volume":"123","author":"Suh","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtcvs.2020.02.131_bib26","unstructured":"Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et\u00a0al. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (version 2.2020). Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf. Accessed February 29, 2020."},{"key":"10.1016\/j.jtcvs.2020.02.131_bib27","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/JTO.0b013e318202bffe","article-title":"Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations","volume":"6","author":"Janjigian","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtcvs.2020.02.131_bib28","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.21037\/jtd.2017.12.58","article-title":"Disease-free survival improved by use of adjuvant EGFR tyrosine kinase inhibitors in resectable non-small cell lung cancer: an updated meta-analysis","volume":"9","author":"Yuan","year":"2017","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.jtcvs.2020.02.131_bib29","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13045-015-0151-3","article-title":"Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status","volume":"8","author":"Zhong","year":"2015","journal-title":"J Hematol Oncol"}],"container-title":["The Journal of Thoracic and Cardiovascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022522320306255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022522320306255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T17:10:01Z","timestamp":1758388201000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022522320306255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0022522320306255"],"URL":"https:\/\/doi.org\/10.1016\/j.jtcvs.2020.02.131","relation":{},"ISSN":["0022-5223"],"issn-type":[{"value":"0022-5223","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gefitinib as neoadjuvant therapy for resectable stage II-IIIA non\u2013small cell lung cancer: A phase II study","name":"articletitle","label":"Article Title"},{"value":"The Journal of Thoracic and Cardiovascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtcvs.2020.02.131","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by The American Association for Thoracic Surgery","name":"copyright","label":"Copyright"}]}}